Table of Contents
- Executive Summary: The State of Gefitinib-Enhanced Lung Fibrosis Research in 2025
- Key Drivers and Restraints Shaping the Market Landscape
- Recent Scientific Breakthroughs and Their Clinical Implications
- Global Market Forecast: 2025–2030 Growth Projections
- Leading Companies and Strategic Partnerships (e.g., astrazeneca.com)
- Emerging Technologies and Therapeutic Platforms
- Regulatory Developments and Policy Updates
- Competitive Analysis: Market Share and Innovation Leaders
- Challenges, Unmet Needs, and Opportunities for Investment
- Future Outlook: What to Expect in the Next 3–5 Years
- Sources & References
Executive Summary: The State of Gefitinib-Enhanced Lung Fibrosis Research in 2025
As of 2025, research into gefitinib-enhanced lung fibrosis remains a critical and evolving area in pulmonary medicine. Originally developed as a first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for non-small cell lung cancer (NSCLC), gefitinib’s adverse effect profile, notably its potential to induce or exacerbate interstitial lung disease (ILD) and lung fibrosis, has prompted sustained investigation across clinical and translational domains. Recent years have seen intensified efforts to characterize the mechanisms, risk factors, and mitigation strategies associated with gefitinib-induced pulmonary fibrotic events, especially as global use of EGFR inhibitors expands.
In 2024-2025, several clinical consortia and academic-industry partnerships have focused on collecting large-scale post-marketing surveillance data and conducting mechanistic studies. Key contributors include AstraZeneca, the original developer and current marketer of gefitinib, which continues to support global safety monitoring and investigator-initiated studies to refine patient selection and risk assessment approaches. U.S. Food & Drug Administration (FDA) and European Medicines Agency (EMA) have both released updated guidance on monitoring and managing ILD in patients treated with EGFR inhibitors, underscoring the recognized clinical significance of drug-induced lung fibrosis.
Recent data from Japanese and European pharmacovigilance programs indicate that the incidence of gefitinib-associated lung fibrosis varies by patient population, with higher rates observed in East Asian cohorts, particularly those with pre-existing pulmonary conditions. Real-world evidence and registry analysis continue to refine estimates of risk—current figures suggest ILD incidence between 1% and 4% among gefitinib-treated NSCLC patients, with a subset progressing to clinically significant fibrosis (Pharmaceuticals and Medical Devices Agency (PMDA)). Collaborative efforts between National Cancer Institute and leading academic centers are underway to identify genetic or molecular biomarkers predictive of susceptibility, aiming for stratified prevention protocols within the next 2-3 years.
Looking forward, the outlook for gefitinib-enhanced lung fibrosis research is defined by development of targeted risk mitigation strategies and novel therapeutic interventions. Ongoing multicenter trials, supported in part by U.S. National Institutes of Health (NIH) grants, are evaluating antifibrotic agents as adjuncts in high-risk patients and exploring modifications to dosing regimens. Meanwhile, International Council for Harmonisation (ICH) guidelines on post-approval safety studies are shaping industry standards for monitoring and reporting. As these collaborative efforts mature, a more nuanced understanding of gefitinib’s pulmonary risks and personalized management approaches is expected to emerge by 2027, improving outcomes for vulnerable patient groups.
Key Drivers and Restraints Shaping the Market Landscape
The landscape of gefitinib-enhanced lung fibrosis research in 2025 is being shaped by a dynamic interplay of scientific advancements, regulatory trends, and evolving clinical needs. Key drivers include a surge in translational research linking EGFR (epidermal growth factor receptor) pathways with pulmonary fibrosis progression, alongside the increasing prioritization of precision medicine approaches for interstitial lung diseases.
One of the main drivers is the rising burden of idiopathic pulmonary fibrosis (IPF) and related fibrotic lung disorders globally, which has intensified the search for novel therapeutics targeting non-cancerous applications of tyrosine kinase inhibitors (TKIs) like gefitinib. Preclinical and early-phase clinical studies have demonstrated that gefitinib, originally developed as an anti-cancer agent, can attenuate fibrotic progression in experimental models by modulating EGFR-driven fibroblast activation. This mechanistic insight has prompted academic and industrial research collaborations aiming to repurpose gefitinib for fibrotic indications, as seen in recent research initiatives supported by entities such as AstraZeneca, the original developer of gefitinib.
Another driver is the acceleration of biomarker discovery and patient stratification strategies that facilitate early identification of patients most likely to benefit from EGFR-targeted interventions. Initiatives by organizations like the National Institutes of Health (NIH) and partnerships between pharmaceutical manufacturers and diagnostic companies are expected to fuel the development of companion diagnostics specific to fibrotic lung disease subtypes.
On the restraint side, safety concerns remain significant. Gefitinib is associated with adverse pulmonary events, including interstitial lung disease (ILD), raising caution about its use in populations already susceptible to lung fibrosis. Regulatory agencies such as the European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA) have issued warnings and require stringent post-market surveillance for TKIs, which may slow the pace of clinical translation.
Intellectual property considerations and market exclusivity issues also play a role, as several generic versions of gefitinib are now available, prompting originator companies to focus on differentiating their compounds through novel formulations or combination regimens. Additionally, competition from other emerging anti-fibrotic agents, such as nintedanib and pirfenidone, is likely to restrain gefitinib’s potential market penetration.
Looking ahead, the market for gefitinib-enhanced lung fibrosis research is expected to witness incremental growth driven by ongoing clinical trials, regulatory harmonization, and expanded academic-industry partnerships. However, the ultimate impact will depend on the ability of researchers and manufacturers to address safety challenges, demonstrate clinical efficacy, and secure regulatory approvals for new indications over the next few years.
Recent Scientific Breakthroughs and Their Clinical Implications
The landscape of lung fibrosis research has seen significant activity surrounding the role of gefitinib, an epidermal growth factor receptor (EGFR) inhibitor, in modulating fibrotic processes. Traditionally, gefitinib has been utilized as an anti-cancer agent, particularly for non-small cell lung cancer (NSCLC). However, recent years have witnessed a pivot in research efforts, focusing on its effects—both therapeutic and adverse—on pulmonary fibrosis.
In 2024 and early 2025, a series of clinical and preclinical studies have provided valuable insights into gefitinib’s dualistic nature in lung tissue remodeling. Investigations led by leading research institutes and pharmaceutical developers have underscored that while gefitinib exhibits anti-fibrotic activity in some experimental models, it may paradoxically exacerbate fibrotic changes under certain conditions. This was highlighted by reports of gefitinib-associated interstitial lung disease (ILD) in a subset of patients, with mechanistic studies indicating that EGFR inhibition can disrupt epithelial repair processes, potentially accelerating fibrogenesis in predisposed individuals (AstraZeneca).
One notable breakthrough in early 2025 is the application of high-resolution single-cell RNA sequencing and advanced imaging modalities to map cellular responses to gefitinib in fibrotic lung models. These technologies have enabled researchers to delineate the heterogeneity of epithelial and fibroblast populations, identifying specific signaling cascades altered by EGFR blockade. Such findings have informed the design of ongoing Phase 2 clinical trials, now recruiting patients with early-stage fibrotic interstitial lung diseases to assess the safety and efficacy of gefitinib as an adjunct to approved anti-fibrotic therapies (National Institutes of Health).
On the translational front, biotech startups and academic consortia are collaborating to develop next-generation EGFR inhibitors with improved selectivity profiles, aiming to minimize adverse fibrotic responses. Regulatory bodies like the European Medicines Agency are actively monitoring post-marketing surveillance data to refine risk mitigation strategies for patients receiving gefitinib, especially those with pre-existing pulmonary conditions.
Looking forward, the next few years are expected to yield critical data from large-scale, multicenter studies evaluating biomarkers for susceptibility to gefitinib-induced lung fibrosis and the efficacy of combination regimens. These insights will likely shape updated clinical guidelines for the optimal use of EGFR inhibitors in both oncology and pulmonary medicine, balancing therapeutic benefits against the potential risk of drug-induced fibrosis.
Global Market Forecast: 2025–2030 Growth Projections
The global market for gefitinib-enhanced lung fibrosis research is poised for significant transformation between 2025 and 2030, driven by advancements in precision medicine and the expanding understanding of fibrotic disease mechanisms. As of 2025, the integration of gefitinib—a well-established EGFR tyrosine kinase inhibitor—into investigational protocols for lung fibrosis is accelerating, with major pharmaceutical and biotechnology firms investing in both preclinical and early-stage clinical studies. This trend is expected to intensify, as several clinical trials targeting idiopathic pulmonary fibrosis (IPF) and related fibrotic lung disorders are scheduled to yield preliminary results by the late 2020s.
The market outlook is strongly influenced by ongoing research collaborations between industry leaders and academic institutions. For instance, AstraZeneca, the original developer of gefitinib, continues to support investigator-initiated research exploring the repurposing of its oncology portfolio for fibrotic indications. Partnerships with leading respiratory research centers are anticipated to increase, fostering innovation in combination therapies and dosing strategies tailored for fibrotic lung disease populations.
Suppliers of research reagents and clinical trial materials, such as Merck KGaA (operating as Sigma-Aldrich) and Thermo Fisher Scientific, report rising demand for gefitinib compounds and related assay kits supporting both basic and translational studies. This increase in procurement reflects broader global interest, particularly from North America, Europe, and East Asia, regions with robust biopharmaceutical pipelines and active governmental support for fibrosis research initiatives.
Projections suggest that, by 2030, the gefitinib-enhanced lung fibrosis research segment could see double-digit annual growth rates, contingent on positive clinical trial outcomes and regulatory advancements. The anticipated launch of next-generation EGFR inhibitors and novel formulations, as developed by companies like F. Hoffmann-La Roche Ltd and Pfizer Inc., may further accelerate translational research and expand market opportunities. The entry of biosimilars and increased focus on cost-effective research tools are also expected to democratize access and foster innovation in emerging markets.
Overall, the 2025–2030 period is set to be pivotal for the gefitinib-enhanced lung fibrosis research market, as stakeholders anticipate breakthroughs that could reshape therapeutic strategies for fibrotic lung diseases worldwide.
Leading Companies and Strategic Partnerships (e.g., astrazeneca.com)
The landscape of gefitinib-enhanced lung fibrosis research in 2025 is shaped by a dynamic interplay among leading pharmaceutical innovators, biotechnology firms, and academic institutions. AstraZeneca, as the original developer of gefitinib (marketed as Iressa), continues to be at the forefront of research exploring the repurposing and mechanistic nuances of gefitinib in fibrotic lung diseases. Building on its established oncology expertise, AstraZeneca has strategically expanded collaborations with respiratory-focused research centers to investigate the dual role of EGFR inhibition in both cancer and non-oncological pulmonary pathologies.
Another prominent actor, F. Hoffmann-La Roche Ltd, leverages its portfolio in pulmonary fibrosis treatments (notably pirfenidone) by engaging in preclinical and translational studies. Roche has entered into research agreements with academic centers to study the synergistic effects of gefitinib and other antifibrotics in models of idiopathic pulmonary fibrosis (IPF), aiming to unravel the molecular interplay and optimize combination regimens.
Biotechnology companies with a focus on fibrotic disease pathways, such as Galapagos NV, have also announced early-stage investigations into EGFR-targeting compounds, including gefitinib, in the context of lung fibrosis. Galapagos’s strategic partnerships with academic consortia are pivotal for high-throughput screening and validation of antifibrotic effects, with a view toward pipeline expansion beyond conventional small molecules.
In the United States, National Heart, Lung, and Blood Institute (NHLBI) continues to fund and coordinate multi-center clinical trials assessing the safety and efficacy of EGFR inhibitors, including gefitinib, in fibrotic lung conditions. These collaborations often involve leading academic hospitals and are expected to yield crucial data by 2026, accelerating the translation of laboratory findings into clinical strategies.
Looking ahead, strategic partnerships are likely to intensify between large pharma, innovative biotech firms, and public research agencies. The goal is to foster data sharing, streamline regulatory pathways, and mitigate risks associated with drug repurposing. With the advent of advanced biomarker platforms and real-world evidence programs, companies such as Astellas Pharma Inc. and Boehringer Ingelheim (both active in pulmonary research) are poised to play a role in next-generation combination trials that include gefitinib or its analogs. The next few years will likely witness the formation of consortium-driven initiatives designed to accelerate the clinical validation of gefitinib-enhanced regimens, potentially reshaping the therapeutic landscape for lung fibrosis.
Emerging Technologies and Therapeutic Platforms
Gefitinib, a first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is traditionally approved for the treatment of non-small cell lung cancer (NSCLC). However, recent years have witnessed a growing interest in its repositioning for fibrotic lung diseases, particularly idiopathic pulmonary fibrosis (IPF) and related progressive fibrosing interstitial lung diseases (PF-ILDs). The rationale is grounded in the observation that EGFR signaling influences fibroblast proliferation and extracellular matrix deposition—central processes in fibrosis pathogenesis.
Since 2024, several research groups and biotechnology companies have accelerated preclinical and early-phase clinical studies to evaluate gefitinib’s anti-fibrotic potential. In 2025, key events include the publication of multi-center preclinical data demonstrating that gefitinib, alone and in combination with other anti-fibrotic agents, can attenuate fibrotic remodeling in murine models of lung injury. These studies, led by collaborative consortia involving major academic centers and pharmaceutical manufacturers, are providing mechanistic insights into gefitinib’s role in modulating epithelial-mesenchymal transition and immune cell infiltration in fibrotic tissue.
In parallel, companies such as AstraZeneca—the original developer and marketer of gefitinib (Iressa)—are supporting investigator-initiated studies to explore off-label applications in fibrotic diseases. Notably, AstraZeneca has stated its commitment to expanding the clinical utility of its oncology portfolio into new therapeutic areas where EGFR signaling is implicated. Early-phase clinical data, expected by late 2025, will focus on safety, pharmacokinetics, and key biomarkers of fibrotic progression in small patient cohorts.
Technological advances are also shaping the research landscape. High-throughput single-cell transcriptomics and spatial omics platforms are being deployed to map the cellular and molecular changes induced by gefitinib in lung tissue. Companies like 10x Genomics and NanoString Technologies are enabling these analyses, facilitating identification of patient subgroups most likely to benefit from EGFR-targeted anti-fibrotic therapy.
Looking ahead to the next few years, the field is poised for further integration of precision medicine approaches. Companion diagnostic development, potentially in partnership with entities such as Roche (a leader in molecular diagnostics), is anticipated to accelerate patient stratification for gefitinib-based interventions. Stakeholders expect that, by 2026–2027, data from ongoing trials and biomarker studies will clarify gefitinib’s position in the therapeutic armamentarium against lung fibrosis, either as monotherapy or in rational combinations with approved anti-fibrotics.
Regulatory Developments and Policy Updates
In 2025, the regulatory landscape concerning Gefitinib-enhanced lung fibrosis research is undergoing significant transformation, reflecting both increased global scrutiny and evolving scientific understanding. Regulatory agencies are closely monitoring the off-label use of Gefitinib—originally an epidermal growth factor receptor (EGFR) inhibitor approved for non-small cell lung cancer (NSCLC)—in experimental protocols for lung fibrosis, particularly idiopathic pulmonary fibrosis (IPF).
The U.S. Food and Drug Administration (FDA) has maintained Gefitinib’s indication for NSCLC but, as of early 2025, is actively evaluating investigator-initiated clinical trials exploring its anti-fibrotic mechanisms. In January 2025, the FDA issued updated guidance to sponsors conducting studies involving kinase inhibitors in pulmonary fibrosis, emphasizing stringent patient safety monitoring and the need for robust preclinical data before progressing to advanced trial stages. These actions coincide with an uptick in Investigational New Drug (IND) applications referencing Gefitinib for fibrotic indications.
Similarly, the European Medicines Agency (EMA) has announced the inclusion of novel anti-fibrotic strategies, including EGFR modulation, in their upcoming 2025-2027 work program. The EMA is reviewing recent submissions from academic consortia and industry sponsors regarding phase II studies evaluating Gefitinib’s efficacy and safety in lung fibrosis cohorts. The agency has reiterated its commitment to adaptive licensing pathways, allowing conditional approvals for promising therapies targeting high-unmet-need conditions such as IPF, provided that post-market evidence generation is robust.
On the policy front, regulatory bodies are also addressing concerns about the potential for drug-induced pulmonary toxicity. Both the FDA and EMA have expanded pharmacovigilance requirements for sponsors using EGFR inhibitors in non-oncology settings. This includes mandatory surveillance for interstitial lung disease (ILD) and mandatory reporting of adverse events, as outlined in updated Risk Evaluation and Mitigation Strategy (REMS) protocols by AstraZeneca, Gefitinib’s originator and global supplier.
Looking ahead, the regulatory outlook for Gefitinib-enhanced lung fibrosis research is cautiously optimistic. Regulatory authorities are expected to publish further guidance on combination regimens and biomarkers for stratifying fibrosis risk in EGFR-targeted trials by 2026. Industry stakeholders anticipate that continued collaboration between manufacturers, research institutions, and regulators will accelerate the responsible development of Gefitinib-based anti-fibrotic interventions, potentially paving the way for new conditional approvals in fibrotic lung disease within the next few years.
Competitive Analysis: Market Share and Innovation Leaders
The competitive landscape of gefitinib-enhanced lung fibrosis research in 2025 is characterized by a blend of established pharmaceutical giants and emerging biotechnology firms striving to extend the therapeutic utility of gefitinib beyond its traditional role in non-small cell lung cancer (NSCLC). Originally developed as an EGFR tyrosine kinase inhibitor, gefitinib’s repositioning for fibrotic lung diseases is increasingly prominent in preclinical and early clinical pipelines.
Key market share is held by AstraZeneca, the original developer and manufacturer of gefitinib under the brand name Iressa™. AstraZeneca continues to drive research collaborations aimed at understanding and expanding gefitinib’s anti-fibrotic mechanisms. In 2024 and 2025, the company has initiated or supported several investigator-led studies evaluating gefitinib’s modulation of fibroblast activity and the epithelial-mesenchymal transition (EMT) central to pulmonary fibrosis.
Alongside AstraZeneca, notable academic-industry partnerships include those involving major research universities and clinical research organizations. For instance, AbbVie and F. Hoffmann-La Roche Ltd have launched exploratory programs assessing combinatorial regimens of gefitinib with novel anti-fibrotic agents, seeking synergistic effects that might slow disease progression or improve lung function in idiopathic pulmonary fibrosis (IPF) models.
In terms of innovation, the focus in 2025 has shifted towards optimizing gefitinib’s delivery and minimizing off-target effects. Several biotech startups, such as Pfizer Inc., have reported advances in targeted aerosolized formulations and nano-carrier systems designed to increase pulmonary bioavailability and reduce systemic toxicity. These technologies are entering early-stage clinical evaluation, backed by internal R&D as well as public-private funding mechanisms.
Furthermore, Boehringer Ingelheim and Novartis are leveraging their established pulmonary portfolios by integrating gefitinib into broader research programs that utilize multi-omics platforms and AI-driven target discovery. These efforts aim to stratify patient populations and optimize intervention timing, potentially leading to precision medicine approaches in fibrotic lung disorders.
Looking ahead, the next few years are expected to see intensified competition as intellectual property positions surrounding gefitinib’s new indications evolve and as biosimilar manufacturers, such as Teva Pharmaceutical Industries Ltd., consider entry into this emerging therapeutic niche. Regulatory pathways will be closely watched, with the potential for accelerated approvals if ongoing trials demonstrate clear clinical benefit in fibrotic lung disease endpoints.
Challenges, Unmet Needs, and Opportunities for Investment
In 2025, the landscape for gefitinib-enhanced lung fibrosis research reveals a complex interplay of challenges, unmet needs, and significant opportunities for investment. Although gefitinib, an EGFR inhibitor primarily approved for certain non-small cell lung cancers, has demonstrated antifibrotic potential in preclinical studies, its application in lung fibrosis remains largely experimental and faces multiple hurdles.
One of the foremost challenges is the limited clinical data supporting gefitinib’s efficacy and safety in treating pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF) and fibrosis following COVID-19 infection. Most current evidence stems from in vitro or animal models, highlighting the urgent need for robust, multicenter clinical trials. The lack of large-scale human studies impedes regulatory pathways and discourages pharmaceutical investment. Additionally, differences in EGFR signaling pathways between fibrotic and cancerous tissues require tailored dosing regimens and safety monitoring, further complicating clinical translation.
An additional unmet need is the development of reliable biomarkers to predict patient response to gefitinib in the context of fibrosis. Without precision diagnostics, patient stratification remains suboptimal, increasing the risk of adverse events and reducing trial success rates. This is compounded by the potential for serious side effects, such as interstitial lung disease (ILD), which has been observed as a rare but significant complication in patients receiving gefitinib for cancer, according to AstraZeneca, the drug’s manufacturer.
Despite these obstacles, the outlook for investment is promising due to several converging factors. The global incidence of lung fibrosis is rising, driven by aging populations and post-pandemic sequelae, creating a substantial and expanding patient base. Interest from biopharmaceutical companies and collaborative initiatives with academic centers are increasing, as seen in recent partnerships and investigator-sponsored studies listed by ClinicalTrials.gov. Advances in molecular profiling and companion diagnostics also pave the way for more targeted clinical trials, with organizations like Roche investing in fibrosis-related biomarker research.
Looking forward, opportunities for investment include funding early-phase clinical trials, supporting biomarker discovery, and developing combination therapies that mitigate side effects while enhancing antifibrotic efficacy. Strategic alliances between industry players, research institutes, and diagnostic companies are likely to accelerate the translation of gefitinib from bench to bedside. As regulatory agencies including the U.S. Food and Drug Administration and European Medicines Agency update their frameworks for fibrosis drug development, stakeholders who invest now stand to benefit from first-mover advantages in this evolving therapeutic area.
Future Outlook: What to Expect in the Next 3–5 Years
As the landscape of lung fibrosis research continues to evolve, the study of gefitinib—a tyrosine kinase inhibitor primarily used for non-small cell lung cancer—has garnered increased attention for its potential to modulate fibrotic pathways. Between 2025 and the late 2020s, several pivotal trends and developments are expected to shape the field of gefitinib-enhanced lung fibrosis research.
A key driver is the mounting evidence from preclinical studies suggesting that gefitinib can attenuate fibrotic responses by targeting the epidermal growth factor receptor (EGFR) pathway, which is increasingly implicated in idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases. As of 2025, multiple academic and industry-sponsored research programs are underway to evaluate gefitinib and similar EGFR inhibitors both as monotherapies and in combination with established anti-fibrotic agents such as pirfenidone and nintedanib.
Over the next three to five years, it is anticipated that early-phase clinical trials will expand, with a focus on patient populations that exhibit EGFR pathway dysregulation. For example, AstraZeneca, the developer and manufacturer of gefitinib, continues to support translational research collaborations aimed at identifying biomarkers that predict response to EGFR inhibition in fibrotic lung disease. These studies are expected to yield data crucial for patient stratification and personalized therapy approaches.
Another significant development is the integration of advanced imaging and molecular diagnostic tools to monitor disease progression and treatment efficacy in real time. Major research hospitals are increasingly implementing these technologies to capture subtle early changes in lung architecture, thus facilitating more robust clinical trial endpoints. Partnerships between pharmaceutical manufacturers and diagnostic technology providers—such as those involving GE HealthCare for imaging solutions—are set to accelerate the validation of these novel endpoints.
From a regulatory perspective, agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have issued guidance encouraging the exploration of repurposed oncology drugs like gefitinib for rare diseases, including fibrotic lung conditions. In parallel, patient advocacy organizations, including the Pulmonary Fibrosis Foundation, are expected to play an increasingly pivotal role in trial recruitment and awareness, contributing to faster study enrollment and greater patient engagement.
By 2028, the lung fibrosis research community anticipates a clearer understanding of gefitinib’s risk-benefit profile in non-cancer settings, alongside new insights into combination regimens and precision medicine strategies. These advances are likely to inform the next generation of therapeutic protocols, potentially offering new hope to patients with progressive and currently incurable lung fibrotic diseases.
Sources & References
- European Medicines Agency (EMA)
- Pharmaceuticals and Medical Devices Agency (PMDA)
- National Cancer Institute
- U.S. National Institutes of Health (NIH)
- International Council for Harmonisation (ICH)
- National Institutes of Health (NIH)
- National Institutes of Health
- Thermo Fisher Scientific
- F. Hoffmann-La Roche Ltd
- Galapagos NV
- National Heart, Lung, and Blood Institute (NHLBI)
- Boehringer Ingelheim
- 10x Genomics
- NanoString Technologies
- Novartis
- GE HealthCare
- Pulmonary Fibrosis Foundation